Long-term outcomes for children with acute lymphoblastic leukemia (ALL) treated on The Cancer Institute of New Jersey ALL trial (CINJALL)

References

• Duffner PK, Armstrong FD, Chen L, et al. Neurocognitive and neuroradiologic central nervous system late effects in children treated on Pediatric Oncology Group (POG) P9605 (standard risk) and P9201 (lesser risk) acute lymphoblastic leukemia protocols (ACCL0131): a methotrexate consequence? A report from the Children’s Oncology Group. J Pediatr Hematol Oncol. 2014;36:8–15.
   PubMed Web of Science ®Google Scholar
• Mahoney DH, Jr, Shuster JJ, Nitschke R, et al. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy – a Pediatric Oncology Group study. J Clin Oncol. 1998;16:1712–1722.
   PubMed Web of Science ®Google Scholar
• Cole PD, Drachtman RA, Smith AK, et al. Phase II trial of oral aminopterin for adults and children with refractory acute leukemia. Clin Cancer Res. 2005;11:8089–8096.
   PubMed Web of Science ®Google Scholar
• Smith A, Hum M, Winick NJ, et al. A case for the use of aminopterin in treatment of patients with leukemia based on metabolic studies of blasts in vitro. Clin Cancer Res. 1996;2:69–73.
   PubMed Web of Science ®Google Scholar
• Cole PD, Drachtman RA, Masterson M, et al. Phase 2B trial of aminopterin in multiagent therapy for children with newly diagnosed acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2008;62:65–75.
   PubMed Web of Science ®Google Scholar
• Cole PD, Zebala JA, Alcaraz MJ, et al. Pharmacodynamic properties of methotrexate and Aminotrexate during weekly therapy. [Erratum appears in Cancer Chemother Pharmacol. 2006 Sep;58(3):418 Note: Zebala, John A [added]]. Cancer Chemother Pharmacol. 2006;57:826–834.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Amer Statist Assoc. 1958;53:457–481.
   Web of Science ®Google Scholar
• Raetz EA, Borowitz MJ, Devidas M, et al. Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a Children’s Oncology Group Study [corrected]. J Clin Oncol. 2008;26:3971–3978.
   PubMed Web of Science ®Google Scholar
• Silverman LB, Stevenson KE, O’Brien JE, et al. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985–2000). Leukemia 2010;24:320–334.
   PubMed Web of Science ®Google Scholar
• Tsurusawa M, Shimomura Y, Asami K, et al. Long-term results of the Japanese Childhood Cancer and Leukemia Study Group studies 811, 841, 874 and 911 on childhood acute lymphoblastic leukemia. Leukemia 2010;24:335–344.
   PubMed Web of Science ®Google Scholar
• Liang DC, Yang CP, Lin DT, et al. Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia. Leukemia 2010;24:397–405.
   PubMed Web of Science ®Google Scholar
• Gaynon PS, Angiolillo AL, Carroll WL, et al. Long-term results of the children’s cancer group studies for childhood acute lymphoblastic leukemia 1983–2002: a Children’s Oncology Group Report. Leukemia 2010;24:285–297.
   PubMed Web of Science ®Google Scholar
• Escherich G, Horstmann MA, Zimmermann M, et al. Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82, 85, 89, 92 and 97. Leukemia 2010;24:298–308.
   PubMed Web of Science ®Google Scholar
• Kamps WA, van der Pal-de Bruin KM, Veerman AJ, et al. Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. Leukemia 2010;24:309–319.
   PubMed Web of Science ®Google Scholar
• Salzer WL, Devidas M, Carroll WL, et al. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children’s oncology group. Leukemia 2010;24:355–370.
   PubMed Web of Science ®Google Scholar
• Moricke A, Zimmermann M, Reiter A, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 2010;24:265–284.
   PubMed Web of Science ®Google Scholar
• Schmiegelow K, Forestier E, Hellebostad M, et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. [Erratum appears in Leukemia. 2010 Mar;24(3):670]. Leukemia 2010;24:345–354.
   PubMed Web of Science ®Google Scholar
• Mitchell C, Richards S, Harrison CJ, et al. Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980–2001. Leukemia 2010;24:406–418.
   PubMed Web of Science ®Google Scholar
• Pui CH, Pei D, Sandlund JT, et al. Long-term results of St Jude Total Therapy studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia 2010;24:371–382.
   PubMed Web of Science ®Google Scholar
• Bleyer WA, Sather HN, Nickerson HJ, et al. Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia: a report of the CCG-161 study by the Childrens Cancer Study Group. J Clin Oncol. 1991;9:1012–1021.
   PubMed Web of Science ®Google Scholar
• Nesbit ME, Jr, Robison LL, Ortega JA, et al. Testicular relapse in childhood acute lymphoblastic leukemia: association with pretreatment patient characteristics and treatment. A report for Childrens Cancer Study Group. Cancer 1980;45:2009–2016.
   PubMed Web of Science ®Google Scholar
• Dordelmann M, Reiter A, Zimmermann M, et al. Intermediate dose methotrexate is as effective as high dose methotrexate in preventing isolated testicular relapse in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 1998;20:444–450.
   PubMed Web of Science ®Google Scholar
• Brecher ML, Weinberg V, Boyett JM, et al. Intermediate dose methotrexate in childhood acute lymphoblastic leukemia resulting in decreased incidence of testicular relapse. Cancer 1986;58:1024–1028.
   PubMed Web of Science ®Google Scholar
• Pui CH, Simone JV, Hancock ML, et al. Impact of three methods of treatment intensification on acute lymphoblastic leukemia in children: long-term results of St Jude total therapy study X. Leukemia 1992;6:150–157.
   PubMed Web of Science ®Google Scholar
• Tsuchida M, Ohara A, Manabe A, et al. Long-term results of Tokyo Children’s Cancer Study Group trials for childhood acute lymphoblastic leukemia, 1984–1999. Leukemia 2010;24:383–396.
   PubMed Web of Science ®Google Scholar
• Bhojwani D, Sabin ND, Pei D, et al. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol. 2014;32:949–959.
   PubMed Web of Science ®Google Scholar
• Malempati S, Gaynon PS, Sather H, et al. Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children’s Oncology Group study CCG-1952. [see comment]. J Clin Oncol. 2007;25:5800–5807.
   PubMed Web of Science ®Google Scholar
• Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol. 2012;30:1663–1669.
   PubMed Web of Science ®Google Scholar
• Yang JJ, Cheng C, Devidas M, et al. Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet. 2011;43:237–241.
   PubMed Web of Science ®Google Scholar
• Salzer WL, Winick NJ, Wacker P, et al. Plasma methotrexate, red blood cell methotrexate, and red blood cell folate values and outcome in children with precursor B-acute lymphoblastic leukemia: a report from the Children’s Oncology Group. J Pediatr Hematol Oncol. 2012;34:e1–e7.
   PubMed Web of Science ®Google Scholar
• Bhatia S, Landier W, Shangguan M, et al. Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children’s oncology group. J Clin Oncol. 2012;30:2094–2101.
   PubMed Web of Science ®Google Scholar
• Harvey RC, Mullighan CG, Chen I-M, et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood. 2010;115:5312–5321.
   PubMed Web of Science ®Google Scholar
• Krajinovic M, Lemieux-Blanchard E, Chiasson S, et al. Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2004;4:66–72.
   PubMed Web of Science ®Google Scholar
• Conter V, Arico M, Basso G, et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia. 2010;24:255–264.
   PubMed Web of Science ®Google Scholar